Genky DrugStores : Summary of Financial Results 2022

Consolidated Financial Results

for the Fiscal Year Ended June 20, 2022

[Japanese GAAP]

July 26, 2022

Company name: Genky DrugStores Co., Ltd.

Stock exchange listing: Tokyo Stock Exchange

Code number: 9267

URL: http://www.genkydrugstores.co.jp

Representative: Kenichi Fujinaga, President

Contact: Takeshi Tsunemi, Executive Officer, Treasurer and General Manager, IR Division

Phone: [phone]

Scheduled date of convention of ordinary general meeting of shareholders: September 9, 2022

Scheduled date of commencing dividend payments: September 12, 2022

Scheduled date of filing annual securities report: September 12, 2022

Availability of supplementary briefing material on annual financial results: Available

Schedule of annual financial results briefing session: Scheduled (for institutional investors and analysts)

(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Fiscal Year Ended June 20, 2022 (June 21, 2021 to June 20, 2022)

(1) Consolidated Operating Results			(% indicates changes from the previous corresponding period.)
														Net income
			Net sales		Operating income	Ordinary income	attributable to owners
														of parent
			Million yen		%	Million yen	%	Million yen	%		Million yen	%
	Fiscal 2021		154,639		-	5,675	-		6,087	-		4,420	-
	Fiscal 2020		142,376		15.2	6,294	45.0		6,601	44.6		4,831	75.4
(Note) Comprehensive income: Fiscal 2021: ¥4,393 million ( - %)
			Fiscal 2020: ¥4,848 million (76.6%)
		Net income			Diluted net		Net income to	Ordinary income	Operating income
					shareholders'
		per share		income per share		to total assets ratio	to net sales ratio
				equity ratio
			Yen				Yen			%			%		%
	Fiscal 2021	291.23				290.88			12.9			6.5		3.7
	Fiscal 2020	318.35				318.03			16.2			7.6		4.4

(Reference): Equity in earnings of affiliates: Fiscal 2021: ¥― million Fiscal 2020: ¥― million

(Note) "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29), etc. has been applied from the beginning of the fiscal year ended June 20, 2022. Therefore, the percentage of changes from the previous corresponding period in actual figures before applying the standard is not presented.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of June 20, 2022	97,118	36,233	37.3	2,383.41
As of June 20, 2021	90,795	32,166	35.4	2,117.96

(Reference) Equity: As of June 20, 2022: ¥36,186 million As of June 20, 2021: ¥32,144 million

(3) Consolidated Cash Flows

Cash flow from

Cash flow from

Cash flow from

Cash and cash

equivalents at the end

operating activities

investing activities

financing activities

of the fiscal year

Million yen

Million yen

Million yen

Million yen

Fiscal 2021

6,076

(10,588)

2,037

5,438

Fiscal 2020

12,075

(8,829)

(1,953)

7,913

2. Dividends

Annual dividends

Total annual

Dividend

Dividend on

payout ratio

equity ratio

1st

2nd

3rd

Year-end

Total

dividends

(consolidated)

(consolidated)

quarter-end

quarter-end

quarter-end

Yen

Yen

Yen

Yen

Yen

Million yen

%

%

Fiscal 2020

－

12.50

－

12.50

25.00

379

7.9

1.3

Fiscal 2021

－

12.50

－

12.50

25.00

379

8.6

1.1

Fiscal 2022

－

12.50

－

12.50

25.00

9.7

(Forecast)

3. Consolidated Financial Results Forecast for the Fiscal Year Ending June 20, 2023 (June 21, 2022 to June 20, 2023)

					(% indicates changes from	the previous	fiscal year.)
							Net income	Net income
	Net sales		Operating income	Ordinary income	attributable to
		per share
							owners of parent
	Million yen	%	Million yen	%	Million yen	%	Million yen	%		Yen
First half	83,000	8.9	2,900	(0.7)	3,075	(1.6)	1,748	(18.0)		115.13
Full year	168,000	8.6	5,800	2.2	6,150	1.0	3,900	(11.8)		256.87

Notes:

1. Changes in significant subsidiaries during the period under review (changes in specified subsidiaries resulting in changes in scope of consolidation): No
   Newly consolidated: None (Company Name); Removed from consolidation: None (Company Name)
2. Changes in accounting policies, changes in accounting estimates and retrospective restatement
3. 1. Changes in accounting policies due to the revision of accounting standards: Yes
   2. Changes in accounting policies other than 1) above: No
   3. Changes in accounting estimates: No
   4. Retrospective restatement: No
4. Total number of issued shares (common stock)

1. Total number of issued shares at the end of the period (including treasury stock): As of June 20, 2022: 15,482,884 shares
   As of June 20, 2021: 15,477,484 shares
2. Total number of treasury stock at the end of the period:

As of June 20, 2022: 300,380 shares

As of June 20, 2021: 300,324 shares

1. Average number of shares during the period: Year ended June 20, 2022: 15,179,544 shares Year ended June 20, 2021: 15,177,219 shares

(Reference) Summary of Non-Consolidated Financial Results

Non-Consolidated Financial Results for the Fiscal Year Ended June 20, 2022 (June 21, 2021 to June 20, 2022)

(1) Non-Consolidated Operating Results				(% indicates changes from the previous fiscal year.)
			Net sales			Operating income		Ordinary income	Net income
			Million yen	%		Million yen	%		Million yen	%	Million yen	%
	Fiscal 2021	318	0.0		113	(19.7)		611	177.6	411	211.1
	Fiscal 2020	318	18.1		141	153.1		220	193.1	132	331.6
			Net income per share	Diluted net income
			per share
				Yen			Yen
	Fiscal 2021			27.09		27.06
	Fiscal 2020			8.71		8.70

(2) Non-Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of June 20, 2022	21,930	21,417	97.4	1,407.50
As of June 20, 2021	23,260	21,343	91.7	1,404.84

(Reference) Equity: As of June 20, 2022: ¥21,369 million As of June 20, 2021: ¥21,321 million

• These financial results are outside the scope of audit by a certified public accountant or an audit corporation.
• Explanation of the proper use of financial results forecast and other notes

The earnings forecasts and other forward-looking statements herein are based on information that is available and certain assumptions deemed reasonable as of the date of publication of this document. Actual results may differ significantly from these forecasts due to a wide range of factors.